Skip to main content

13-023 - Method for reducing incidence of fibrosis caused by peritoneal dialysis

Researchers

Alireza R. Rezaie and Peyman Dinervand

Summary

Peritoneal dialysis is an alternative to hemodialysis as a treatment for end-stage renal disease and is based on the use of the peritoneum as a permeable membrane whereby ultrafiltration and diffusion between dialysate and blood can take place across the peritoneum. During continuous ambulatory peritoneal dialysis (CAPD) chronic injury occurs which leads to failure of filtration. This invention relates to the use of activated Protein C (APC) as a therapeutic drug for inhibiting dialysis-mediated peritoneal fibrosis.

Intellectual Property Status

  • U.S. patent pending